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Abstract 
The trimorphism of the active pharmaceutical ingredient piracetam is a famous case of 
polymorphism that has been frequently revisited by many researchers. The phase 
relationships between forms I, II, and III were ambiguous because they seemed to 
depend on the heating rate of the DSC and on the history of the samples or they have not 
been observed at all (equilibrium II-III). In the present paper, piezo-thermal analysis 
and high-pressure differential thermal analysis have been used to elucidate the 
positions of the different solid-solid and solid-liquid equilibria. The phase diagram, 
involving the three solid phases, the liquid phase and the vapor phase, has been 
constructed. It has been shown that form III is the high-pressure, low-temperature form 
and the stable form at room temperature. Form II is stable under intermediary 
conditions and form I is the low pressure, high temperature form, which possesses a 
stable melting point. The present paper demonstrates the strength of the topological 
approach based on the Clapeyron equation and the alternation rule when combined 
with high-pressure measurements. 
 
Keywords: Calorimetry, Crystal polymorphism, X-ray powder diffractometry, Solid 
state, Phase diagram, Phase transition, Physical characterization, Physical stability, 
Preformulation, Thermodynamics 
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1 Introduction 
1.1 The stability hierarchy of the three solid forms of piracetam 
The stability hierarchy of polymorphs is often based on transition temperature 
measurements by DSC and illustrated by schematic diagrams representing the Gibbs 
energy as a function of temperature.1,2 However, it may happen that this approach is 
incomplete and the trimorphism of piracetam is such an example for which the stability 
hierarchy remains unsolved. It is known for over a decade that forms II and III both 
transform endothermically into form I on heating; however, the onset temperatures of 
the two solid-solid transitions at equilibrium are not known, as they appear to depend 
on the investigator and on the sample used. 
Kuhnert-Brandstätter et al. report an energy-temperature diagram in which the 
transition temperature of form II into form I (TII→I) is about 348 K when measured by 
thermomicroscopy or about 377 K when measured by DSC.3 As the transition 
temperature of form III into form I (TIII→I) is about 388 K when measured by DSC, which 
is higher than TII→I, the authors conclude that form III is the more stable phase at room 
temperature.3 They also mention that “the relative high stability of mod. II can be 
explained by the small difference of energetic data between mod. II and mod. III.“ 
Picciochi et al. concluded that “the results of solution and DSC experiments indicate that 
the stability hierarchy of forms I, II, and III at 298.15 K … is III > II > I“.4 
Maher et al. reported a ∆G - T diagram exhibiting endothermic transitions II→I and III→I 
below 363 K and below 368 K respectively, thus leading to the conclusion that form III is 
the more stable form below 368 K.5 
Céolin et al. reported that the endothermic transitions III→I and II→I occur at 392 K and 
399 K respectively, thus inferring that form II is the more stable phase below 392 K.6 
Although a tendency can be observed that form III is the more stable phase at room 
temperature, the large variation of solid-solid transition temperatures in the different 
papers warrants an alternative approach to determine the stability hierarchy of the 
polymorphs without ambiguity. In this paper, it will be demonstrated how the stability 
hierarchy can be inferred from experimental pressure-temperature diagrams. 
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1.2 Literature data 
1.2.1 Crystallographic data  
Three solid forms of piracetam (C6H10N2O2, M = 142.16 g mol-1) have been structurally 
characterized under ambient conditions (Table 1 and Table S1 in the Supporting 
Information), and two more forms as well as two hydrates have been obtained under 
pressure: form IV (monoclinic, P21/c),7 form V (triclinic, P-1),8 a monohydrate,7 and a 
dihydrate8. From the data in Table 1, it can be inferred that form III is the denser form, 
while form I is the less dense one.  
 
Table 1. Specific volumes (v) from the literature of the three solid forms of 
piracetam obtained under ambient conditions 
Form System, space group v 
/cm3 g-1 
T 
/K 
Ref. 
I Monoclinic P21/n 0.7661 
0.7518 
R.T. 
150 
9 
7 
II Triclinic P-1 0.7383 
0.7094 
R.T. 
100 
10 
11 
III Monoclinic P21/n 0.7216 
0.7321 
0.7245 
0.7251 
0.7058 
R.T. 
R.T. 
R.T. 
290 
100 
12 
10 
13 
14 
11 
1.2.2 Calorimetric data 
The thermal behavior of piracetam polymorphs has been described by several authors 
(see Table 2). From the data in Table 2, it can be inferred that ∆II→Ih is consistently 
smaller than ∆III→Ih by 3 to 6 J g-1. The melting point of form II, TII→L, was reported to be 
415.5 K3 or 415 K6, but this information should be considered cautiously because it is 
based on the optical observation of a change in morphology3 or the presence of a very 
small endothermic peak in a few DSC curves6. 
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Table 2. Calorimetric data for piracetam forms I, II, and III from the literature 
TII-I 
/K 
∆II→Ih 
/J g-1 
TIII-I 
/K 
∆III→Ih 
/J g-1 
TI-liq 
/K 
∆I→liqh 
/J g-1 
TIII-liq 
/K 
∆III→liqh 
/J g-1 
Ref. 
382 
382 
23.71 
23.92 
393 
392 
26.45 
26.73 
- 
423 
- 
179.38 
- 
- 
- 
- 
15 
5 
348 or 377 21 390 26.7 426 180.7 413 206 3 
399 24 392 28 426 180 412 210 6 
382.7 22.72 394.4 26.24 425.9 176.6 or 
182.9 
  4 
2 Material and Methods 
2.1 Samples 
Piracetam forms II and III of medicinal grade were obtained from Isochem, France. They 
were used as such after verification by differential scanning calorimetry and high-
resolution X-ray powder diffraction. Form I, which is not persistent at RT, was obtained 
from either of these polymorphs by heating above the transition temperature and 
quenching.6 
2.2 Differential scanning calorimetry 
Three DSC analyzers were used to determine the temperatures and heats of transition: a 
TA Instruments (USA) DSC10 Differential Scanning Calorimeter, a Q100 thermal 
analyzer from TA-Instruments (USA), and a Mettler-Toledo (Switzerland) 822e thermal 
analyzer. Indium (Tfus = 429.75 K, ∆fusH = 3.267 kJ·mol-1) and zinc (Tfus = 692.68 K, ΔfusH 
= 7.320 kJ·mol-1) were used as standards for temperature and enthalpy calibration. 
Specimens were weighed with microbalances sensitive to 0.01 mg and sealed in 
aluminum pans. 
2.3 High resolution X-ray powder diffraction 
Two series of non-ambient X-ray powder diffraction data were obtained for the thermal 
expansion study. 
A Bragg-Brentano optics was used with a Bruker D5005 powder diffractometer, 
equipped with an Anton Paar high-temperature oven camera HTK1200. Cu Kα1,2 X-rays 
were obtained with a diffracted-beam graphite monochromator. Powders were pressed 
on a Ni grid sample-holder in order to reduce transparency effects. Samples of forms II 
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and III were heated above 400 K and upon cooling form I was observed. It must be noted 
that volume changes during phase transformations may affect the quality of the sample 
surface (the volumes per formula units are 4.6% and 3.8% greater for form I than for 
forms III and II, respectively). The powder data were collected at selected temperatures 
under air. Previous diffraction studies showed a short life time of samples of form I 
obtained from samples of forms II and III quenched at room temperature.6 To reduce the 
time required for data collection, the diffraction patterns were scanned over the angular 
range 10-35° (2θ), with a step size of 0.025° (2θ) and 3 s step-1. Due to the low counting 
statistics, the accuracy of the results is moderate. The peak positions were evaluated 
with the software WinPLOTR.16 For each pattern the better defined diffraction lines 
were selected and twenty peak positions were input in the indexing program 
DICVOL14.17 The cell parameters are least-squares refined, as well as the zero-point 
position of the patterns. 
A Debye-Scherrer optics was used with an INEL powder diffractometer equipped with a 
cylindrical position-sensitive detector (CPS120) containing 4096 channels (0.029° 2θ 
angular step) and monochromatic Cu Kα1 (λ = 1.54061 AX ) radiation. For the 
measurements as a function of temperature, a liquid nitrogen 700 series Cryostream 
Cooler from Oxford Cryosystems (UK) was used. Slightly ground specimens were 
introduced in a Lindemann capillary (0.5 mm diameter) rotating perpendicularly to the 
X-ray beam during the experiments to improve the average over the crystallite 
orientations. For the temperature-dependent measurements in the range from 100 K up 
to the melting point, the sample temperature was equilibrated for about 10 min followed 
by an acquisition time of ca. 1 hour. The heating rate in between data collection was 1.33 
K min-1. The powder data were analyzed with the software FULLPROF using pattern 
matching.18 
2.4 Specific volume of molten piracetam 
10.1223 g of piracetam (weighed with a microbalance sensitive to 0.1 mg) was 
introduced in a cylindrical silica tube with a flat bottom, whose mean inner diameter 
(8.152 mm) was obtained with a DIGI-MET® 3-point alesometer with a precision of 
0.003 mm (see below Table S7, Supporting Information). After being sealed under 
vacuum, the tube was suspended in a XU 75/300 oven from Climats (France) whose 
inner temperature, controlled at ±1 K, was allowed to vary slowly between successive 
measurements in the 390 - 470 K range. The height of the melt was measured through 
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the window of the door of the oven with a cathetometer sensitive to 2 μm. 
2.5 Sublimation-condensation experiment 
A specimen of form III was placed at one end of a cylindrical silica tube (29 cm length), 
which was sealed under vacuum. It was introduced in a horizontal furnace so that the 
specimen-containing end was maintained at about 414 K and the other end was outside 
the furnace at room temperature. Crystals grew by condensation of the vapor phase 
within 6 days (Figure 1). 
 
 
Figure 1. Sublimation-condensation of piracetam crystals in a silica tube subjected to a 
temperature gradient for 6 days. The initial sample (form III) was placed in the small 
container on the left-hand side and maintained at 414 K. 
2.6 Piezo-thermal analysis (PTA) 
An in-house constructed piezo-thermal analyzer, whose operating principle and design 
have been described elsewhere,19-22 was used to record the thermal effects associated 
with phase transitions investigated isothermally as a function of pressure. Pressure was 
gradually decreased under isothermal conditions at a rate of 20 or 50 MPa h-1 from a 
maximum pressure of 600 MPa down to atmospheric pressure. The measurement range 
for the temperature of the equipment is 298 to 490 K. The weight of the specimens 
(about 15 mg) was determined with a microbalance sensitive to 0.01 mg. It is important 
to point out that PTA allows precise entropy change measurements as a function of 
pressure because the fluxmeter of the device records enthalpy changes at constant 
temperature. 
2.7 High-pressure differential thermal analysis. 
The transitions in piracetam have been studied with high-pressure differential thermal 
analysis (HP-DTA). An in-house constructed HP-DTA, similar to the apparatus 
previously built by Würflinger23 with temperature and pressure ranges from 203 to 473 
K and 0 to 300 MPa, respectively, was used. Unweighed samples (about 10 to 50 mg) 
were sealed in cylindrical tin pans and to ensure that in-pan volumes were free from 
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residual air, specimens were mixed with an inert perfluorinated liquid (Galden® from 
Bioblock Scientifics, Illkirch, France) before sealing. HP-DTA scans were carried out with 
a heating rate of 2 K min-1. In addition, DSC experiments at ordinary pressure (i.e., in 
standard aluminum pans) with mixtures of piracetam and perfluorinated liquid were 
carried out to verify that the liquid was inert. 
3 Results 
3.1 Calorimetric data 
Two series of experiments were carried out to investigate whether the transition 
temperatures II→I and III→I depend on the history of the samples (see details in the 
Supporting Information Tables S2 and S3). It can be seen in Figure 2a that the 
temperature intervals in which the two solid-solid transitions occur fully overlap at the 
heating rates of 5 and 10 K min-1. 
Hence, aliquots of forms II and III were ground to obtain fine powders with about the 
same grain size (verified by optical microscopy). Each has been heated at various rates 
to investigate their dependence on the heating rate and to compare the two samples. 
From the data, shown in Figure 2b (see also the Supporting Information Table S2-S5), 
the following has been concluded: (1) the melting temperature of form I is virtually 
independent of the heating rate, (2) transitions III→I and II→I are heating-rate 
dependent, and (3) it is inconclusive which of the two forms transforms at the lowest 
temperature into form I. It is not uncommon to observe solid-solid transitions that are 
heating rate dependent;24-26 however a complete overlap in temperature range of two 
distinct transitions is rare. 
A statistical analysis of the transition temperatures for the two solid-solid transitions 
obtained with heating rates of 5 and 10 K min-1 (see Supporting Information Tables S2 
to S5) is entirely inconclusive as to which of the two forms, II or III, transforms into form 
I first: TII→I 390.62 K and TIII→I 389.04 K (TII→I: 12 values, min 372.35 K, max 402.82 K, σ 
= 9.4 K and TIII→I: 18 values min 363.33 K, max 406.86 K, σ = 12.5 K). Average values of 
the transition quantities (compiled in the Tables S2 to S5 in the Supporting Information) 
have been reported in Table 3. 
Page 8 of 55
John Wiley & Sons, Inc.
Journal of Pharmaceutical Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 9 
 
Figure 2. Onset temperatures of transitions II→I (solid squares), III→I (open circles) 
and melting of form I (solid diamonds) (A) of samples obtained by different methods 
and heated at 5 or 10 K min-1 (see for details Table S2 to S5) and (B) as a function of the 
heating rate. 
 
Some unground specimens of form III crystals obtained from methanol did not 
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transform to form I but melted. Tentatively, this could be explained by the presence of 
methanol in the crystal at a level of about 1 % of the initial mass, as determined by 
thermogravimetric analysis. Thus, methanol as an impurity may be able to stabilize form 
III up to its melting point. However, this also means that the specific melting enthalpy of 
form III obtained from these measurements needs to be corrected for the solvent 
weighed in before the measurement run. Thus, the apparent melting enthalpy for form 
III from the measurements is 1 % smaller than the actual value for pure form III. The 
melting enthalpy has been corrected for this error as reported in Table 3. It is clear that 
the experimental ∆III→liqh virtually matches the value 214.62 J g-1 calculated by adding 
∆III→Ih to ∆I→liqh. 
 
Table 3. Summary of the calorimetric data obtained for forms I, II, and III of 
piracetam from 5 series of DSC experiments (see Tables S2 to S5 in the Supporting 
Information) 
 Number 
of values 
Lowest 
value 
Highest 
value 
Mean Standard 
deviation 
TII-I /Ka 12 372.9 402.8 390.6 9.4 
TIII-I /Ka 18 363.3 406.9 389.0 12.5 
∆II→Ih/J g-1 23 22.9 25.9 24.4 0.9 
∆III→Ih/J g-1 26 25.2 30.1 27.5 1.2 
∆I→liqh/J g-1 49 174.9 195.4 187.1 4.3 
TI-liq/K 49 423.3 425.6 424.5 0.5 
∆III→liqh/J g-1 7 (205.0) 
207.1b 
(217.1) 
219.3b 
(211.5) 
213.6a 
4.4 
TIII-liq/K 7 411.9 412.8 412.3 0.34 
aAverage for 5 and 10 K min-1 only 
bValues adjusted for the presence of 1 mass% of methanol in form III, the measured 
apparent melting enthalpies are provided in parentheses. 
3.2 Sublimation-condensation experiment 
As can be seen in Figure 1, big crystals deposited in the temperature range from 390 
down to 360 K, while small crystals had formed in the colder part of the tube below 360 
K. X-ray diffraction of ground big crystals (390-360 K range) led to the diffraction 
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pattern of form II. The small crystallites formed below 360 K exhibited a mixed 
diffraction pattern of forms II and III. Taking the calorimetric measurements into 
account, it would be expected that above 360 K form I deposits. After the tube is 
extracted from the furnace and cooled to room temperature, form I will have 
transformed relatively rapidly to form II. This has also been observed previously by X-
ray diffraction.6 The simultaneous observation of form II and form III crystals just above 
and at ambient temperature demonstrates that any stability difference between them is 
probably rather small. 
3.3 Specific volume and thermal expansion of forms I, II, and III 
Two series of experiments as a function of temperature have been carried out. The data 
are compiled in the Supporting Information Tables S6a and S6b. Using all available data 
for the specific volumes (vI, vII, and vIII in cm3g-1) as a function of temperature (K), the 
following three equations were obtained: 
 
vI = 0.7219 + 0.00016026 T   r2 = 0.960   (1) 
 
vII = 0.69661 + 0.00013037 T  r2 = 0.992   (2) 
 
vIII = 0.69341 + 0.00011618 T  r2 = 0.993   (3) 
 
Expressed in expansivities, the expressions lead to αv,I = 2.22×10-4 K-1, αv,II = 1.87×10-4 
K-1, and αv,III = 1.68×10-4 K-1. These expansivities are all near the value of 2×10-4 K-1 
reported by Gavezzotti for organic molecular compounds27 and for organic molecular 
APIs a similar trend has been observed.28,29 In addition, it can be seen in Figure 3 that 
the eqs. 1-3 are in close agreement with volumes obtained from single crystals at 100 
and 150 K for all three forms. 
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Figure 3. Specific volumes of piracetam forms I (open circles, eq. 1), II (solid diamonds, 
eq. 2) and III (solid circles, eq. 3) as a function of temperature from high-resolution X-
ray powder diffraction and comparison with volumes from single crystal structures (a: 
ref 8, b and c: ref 11). The experimental (eq. 4a, open diamonds) and calculated (eq. 4b, 
dashed line, see text) specific volumes of liquid piracetam are also provided. 
3.4 Specific volume of molten piracetam as a function of temperature 
The specific volume obtained by measurement of liquid piracetam as a function of 
temperature is presented in Figure 3 (compiled in the Supporting Information in Table 
S7). The data is fit to the expression (units as in eqs. 1-3): 
 
vliq = 0.6291 + 0.0005952 T  r2 = 0.994    (4a) 
 
Molecular organic compounds (including pharmaceuticals) often degrade in the molten 
state and therefore eq. 4a should be considered as approximate. However, this 
expression can be compared to the liquid expansion obtained via a different approach. 
The thermal expansion of the liquid can be estimated assuming that: (1) the specific 
volume of the melt at the temperature of fusion is in the order of 1.11 times the specific 
volume of its solid and (2) the mean expansivity αv,liq of the melt is 1.2 ×10-3 K-1.28-31 
With these two approximations, one obtains the dependence of the specific volume of 
the melt on the temperature (units as eqs. 1-4a): 
 
vliq = 0.5810 + 0.0006971 T       (4b) 
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This equation leads to values close to the experimental ones in the temperature range 
from 420 to 500 K (Figure 3). 
3.5 Piezo-thermal analysis 
The melting pressures (P /MPa) of forms I and III have been measured isothermically in 
decreasing pressure runs for a set temperature in the temperature range of 412 to 443 K 
together with the transition enthalpy, leading also to the entropy and specific volume 
changes (see the Supporting Information Table S8 for numerical data). The P,T melting 
curves were fitted to straight lines: 
 
PI-liq = -2529 + 5.956 T  r2 = 0.998    (5a) 
 
PIII-liq = -1878 + 4.555 T  r2 = 0.997    (6a) 
 
When decreasing the pressure in the apparatus from a pressure higher than 200 MPa, 
the transition III→I was always observed, also for samples that were initially loaded as 
form II. This indicates that form II transforms into form III under a sufficiently high 
pressure i.e. >200 MPa. Measurement runs of form II starting below 200 MPa, in 
contrast, gave rise to the II→I transition on decreasing the pressure. 
Transitions III→I and II→I could be easily identified by their respective enthalpies (see 
Table 3). The resulting P (MPa), T (K) data are reported in the Supporting Information 
Table S9. They were fitted to the following straight lines: 
 
PIII-I = -681.2 + 1.886 T  r2 = 0.987    (7a) 
 
PII-I = -899.5 + 2.409 T  r2 = 0.992    (8a) 
 
The enthalpy changes obtained at high pressure (see the Supporting Information Tables 
S8 and S9) are similar to the values obtained in a standard DSC apparatus and virtually 
no change is observed (within the experimental limits). 
3.6 High-Pressure Thermal Analysis 
The temperatures (T/K) of fusion of forms I and III measured at different pressures 
(P/MPa) are compiled in the Supporting Information Table S10. Linear fits to the data 
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lead to the following equations: 
 
PI-liq = -3714 + 8.728T  r2 = 0.968    (5b) 
 
PIII-liq = -1978 + 4.814 T  r2 = 0.993    (6b) 
 
PIII-I = -785.7 + 2.118 T  r2 = 0.964    (7b) 
 
PII-I = -1531+ 3.933 T  r2 = 0.958    (8b) 
 
4 Discussion 
4.1 Preliminary phase diagram using only experimental data points 
The aim of the discussion is to construct a complete pressure-temperature phase 
diagram of the trimorphism of piracetam in combination with the stability hierarchy of 
the different equilibria and phases. In first instance, the experimental P-T data will be 
taken into consideration and this will subsequently be completed through 
thermodynamic arguments and other data. 
For certain high-pressure measurements, different slopes can be observed for the same 
transition depending on the method used (cf. eqs. 8a and b). Nevertheless, irrespective 
of the method, the inequalities between the dP/dT slopes of the two-phase equilibria is 
consistently dP/dT I-liq > dP/dT III-liq > dP/dTI-II > dP/dTI-III. This is illustrated in Figure 4 
with expressions using the combined data from both high-pressure methods: 
 
PI-liq = -3109 + 7.317 T  r2 = 0.914    (5c) 
 
PIII-liq = -2022 + 4.904 T  r2 = 0.990    (6c) 
 
PIII-I = -676.8 + 1.871 T  r2 = 0.977    (7c) 
 
PII-I,PTA = -899.5 + 2.409 T  r2 = 0.992    (8a) 
 
PII-I,HP-DTA = -1531 + 3.933 T  r2 = 0.958    (8b) 
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Figure 4. Pressure-temperature phase diagram of the phase transitions of piracetam 
with experimental data points only. Fusion of form I: squares, fusion of form III: 
diamonds, III→I: plus sign, II→IPTA: circles, and II→IHP-DTA: triangles. 
 
The high-pressure results from the two different methods could be smoothly combined 
into single expressions with the exception of transition II→I whose HP-DTA curve is 
steeper and clearly separated from the curve obtained by PTA. Nevertheless, it can be 
observed that both lines converge at the exact same point (point ‘a’ in Figure 4), where 
the I-III equilibrium line intersects. It is therefore likely that point ‘a’ is the I-II-III triple 
point. Because piezothermal analysis is an isothermal method, the temperatures at 
which transitions are observed are not heating-rate dependent, therefore, it could be 
suggested that the line ‘a-a1’ in Figure 4 coincides more accurately with the I-II 
equilibrium line. 
It should also be noted that, although the whole line ‘b-c’ has been identified as the 
equilibrium I-III through its enthalpy value, once this line intersects the triple point I-II-
III (point ‘a’) it must change its stability ranking. 
If no hydrostatic pressure is applied (i.e. in a standard DSC) transitions III→I and II→I 
should ideally be observed at 361.7 K (eq. (7c)) and 373.4 K (eq. (8a)), respectively. 
Since curve ‘a-a2’ in Figure 4 converges with curves ‘a-a1’ and ‘b-c’ at point ‘a’, it may be 
tentatively inferred that the influence of the heating rate on the temperature of 
transition II→I decreases with increasing pressure. 
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It is also clear that the I-III-liq triple point (where the equilibria I-III, I-liq, and III-liq 
intersect, point ‘b’ in Figure 4) will be located at a lower temperature than that of triple 
point I-II-liq (Not shown in Figure 4) because equilibrium I-III crosses equilibrium I-liq 
at a lower temperature than equilibrium I-II does. 
4.2 Triple point I-II-III and equilibrium curve II-III 
Triple point I-II-III is the intersection of the I-II and I-III equilibrium curves (point ‘a’ in 
Figure 4). Thus, by setting eqs. (7c) and (8a), or (7c) and (8b) equal, the coordinates of 
triple point I-II-III are found to be TI-II-III ≅ 414 K and PI-II-III ≅ 95.5 MPa. 
Equilibrium II-III must pass through triple point I-II-III too, even though it has not been 
observed experimentally. To determine the value of its dP/dT slope, one can make use of 
the fact that the equalities ΔIII→IIs = ΔIII→Is - ΔII→Is and ΔIII→IIv = ΔIII→Iv - ΔII→Iv hold at the 
triple point I-II-III. Using mean ∆s and ∆v values calculated with the values compiled in 
Table S9 in the Supporting Information, one finds ΔIII→IIs = 0.078 – 0.068 = 0.010 J K-1g-1, 
and ΔIII→IIv = 0.0385 - 0.0282 = 0.0103 cm3g-1, which results in a dP/dTII-III of 0.97 MPa K-
1 through the Clapeyron equation: 
 
dP/dT = Δs/Δv = Δh/(TΔv)       (9) 
 
Using the triple point as a coordinate on the II-III equilibrium line one finds for its P 
(/PMa) – T (/K) relationship: 
 
PII-III = -306 + 0.97 T        (10) 
 
At PII-III = 0 MPa, eq. 10 becomes 316 K. This is the temperature for triple point II-III-vap, 
as the vapor pressure of molecular substances around room temperature generally 
ranges between a few pascal up to a few hundred pascal and P in megapascal is 
approximately zero. 
The slope of eq. 10 has been calculated using the entropy obtained by PTA. If instead one 
uses the mean enthalpy changes obtained in a standard DSC (Table 3), as would be the 
case for the topological approach, the entropy difference between forms II and III will be 
0.0077 J K-1 g-1 at the triple point temperature of 414 K. Using the volume change 
obtained by X-ray diffraction vII-vIII = 0.00907 cm3g-1 at 414 K (eqs. 2 and 3), the slope 
dP/dTII-III calculated with eq. 9 is 0.85 MPa K-1, i.e. near the value in eq. 10 and clearly 
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the shallowest slope of all equilibrium curves. 
The use of specific volumes obtained at ordinary pressure is validated by a reported 
density increase of approximately 5 % between 0 and 0.5 GPa for form II.8 Triple point I-
II-III is found at about 0.1 GPa, thus it can be safely assumed that the decrease in the 
specific volumes of the three solid phases is in the order of 1%. 
4.3 Triple points I-III-liq and II-III-liq 
The coordinates of triple point I-III-liq in the P,T diagram of piracetam can be most 
easily found by setting the equations for the equilibria I-III and III-liq (6c and 7c) equal. 
These two equilibria are experimentally better defined than the I-liq equilibrium curve. 
The coordinates of triple point I-III-liq are found to be TI-III-liq = 443.5 K and PI-III-liq = 153 
MPa. 
For the II-III-liq triple point, the intersection of curves II-III and III-liq, the P,T 
coordinates are found by setting equations 10 (II-III) and 7c (III-liq) equal: TII-III-liq = 436 
K and PII-III-liq = 117 MPa. This is lower in temperature as well as in pressure than the 
coordinates of triple point I-III-liq. 
4.4 II-liq melting curve and triple point I-II-liq 
The melting point of form II (or triple point II-liq-vap if the melting takes place under 
saturated vapor pressure) has not yet been determined convincingly, as a clear melting 
peak in the DSC has never been observed. An estimate can be obtained by determining 
the slope of the II-liq equilibrium at the triple point II-III-liq (which has just been 
obtained) and by extrapolating the obtained expression of the II-liq equilibrium 
downwards to its saturating vapor pressure. Approximating the equilibrium curve by a 
straight line, dP/dT can be determined following the same procedure as used above for 
the II-III equilibrium line. At triple point II-III-liq, equalities ΔII→liqs = ΔIII→liqs - ΔIII→IIs and 
ΔII→liqv = ΔIII→liqv - ΔIII→IIv hold. Because both enthalpy and volume changes for the 
melting of form III appeared to depend slightly on the temperature and pressure (see 
data in Table S8), their values have been calculated with equations S8a and S8b (derived 
from Table S8). ΔIII→IIs = 0.01 J K-1g-1 (section 4.2) and ΔIII→liqs = 0.48 J K-1 g-1 (eq. S8a 
evaluated at triple point II-III-liq) give ΔII→liqs = 0.47 J K-1 g-1, while ΔIII→IIv = 0.01030 cm3 
g-1 (section 4.2) and ΔIII→liqv = 0.10535 cm3 g-1 (eq. S8b evaluated at triple point II-III-liq) 
result in ΔII→liqv = 0.09505 cm3 g-1. Thus, dP/dTII→liq = 0.47/0.09505 = 4.94 MPa K-1, and 
with PII-III-liq = 117 MPa and TII-III-liq = 436 K, the linear equation for curve II-liq becomes: 
Page 17 of 55
John Wiley & Sons, Inc.
Journal of Pharmaceutical Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 18
 
PII-liq = -2040 + 4.94 T       (11a) 
 
This equation gives TII-liq-vap = 413 K at P = 0 MPa. This value, slightly higher than TIII-liq-
vap = 412.34 K (see Table 3), is in close agreement with the observation of Kuhnert-
Brandstätter et al. by optical microscopy that the melting of crystals assumed to be 
forms II and III occurred at 415.5 K and 413 K, respectively.3 
 
The triple point I-II-liq is the intersection of equilibrium curves I-II, I-liq, and II-liq. 
Setting eqs. 5c and 11a equal for curves I-liq and II-liq, respectively, the triple point 
coordinates TI-II-liq = 450 K and PI-II-liq = 182 MPa are obtained. A second combination of 
equations 5a (I-liq) and 8a (I-II) from PTA data only leads to the coordinates TI-II-liq = 459 
K and PI-II-liq = 207 MPa, i.e. higher but still comparable to the foregoing results. Finally, 
using eqs. 8a and 11a (II-liq), TI-II-liq = 451 K and PI-II-liq = 186 MPa are found, which is also 
near the previous values. Moreover in all cases, the triple point coordinates are higher 
than those of triple point I-III-liq. 
4.5 Construction of the complete P-T diagram 
A phase diagram involving three crystalline forms possesses ten triple points 
irrespective of their relative stabilities.32 Three triple points, I-liq-vap, II-liq-vap, and III-
liq-vap, are located on the liq-vap equilibrium, the saturating vapor pressure of the 
liquid. This equilibrium separates the phase diagram into a high-pressure and a low-
pressure part. In the low-pressure domain, three more triple points are located, I-II-vap, 
I-III-vap, and II-III-vap, all part of the condensed-phase – vapor equilibria. In the high-
pressure domain, another four triple points, I-II-III, I-II-liq, I-III-liq, and II-III-liq are 
located. 
4.5.1 Regions involving only condensed phases 
Using the results obtained or inferred from PTA and HP-DTA experiments, the diagram 
shown in Figure 5 represents the high-pressure domain with the condensed phases. It is 
important to realize that an equilibrium curve passing through a triple point must 
change its stability level. In fact, around a triple point, the stability ranking must 
alternate for each equilibrium line, as can be seen for triple point I-II-III, where line 4 
below is stable, line 5 is metastable (broken line), line 6 is stable, continuing clockwise, 
equilibrium 4 is encountered again, which is now metastable etc. This fact, which is due 
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to the intersecting Gibbs energy surfaces of which the pressure-temperature phase 
diagram is a projection, is called the alternation rule.33,34 The alternation of the two-
phase equilibria around the different triple points can be clearly observed in Figure 5a. 
Once the stability rank of one of the triple points has been determined, the ranks of the 
others are defined and therefore also those of the different two-phase equilibria. The 
result is presented in Figure 5. 
 
Figure 5a. Location of the triple points in the P-T region involving only condensed 
phases. Two-phase equilibrium curves: 1: I-liq, 2: II-liq, 3: III-liq, 4: I-II, 5: I-III, and 6: II-
III. Filled circles: stable triple points, half-filled circles: metastable triple points. Solid 
lines: stable equilibria, dashed lines: metastable equilibria, dotted lines: super –
metastable equilibria. Stable phase regions: dark grey: liquid, white: form I, medium 
grey: form II, light grey: form III. 
 
Figure 5b. Detail of the P-T diagram with the three triple points along the liq-vap curve 
(= x-axis): solid circle: I-liq-vap, stable, half-filled circle: II-liq-vap, metastable, open 
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circle: III-liq-vap, super-metastable. The diagram shows the same two-phase 
equilibrium lines as in Figure 5a. Stable phase regions: see Figure 5a. 
 
The results presented in Figure 5 and obtained by high-pressure measurements and 
thermodynamic inferences can be compared to a phase diagram obtained by the 
topological method based on the Clapeyron equation and the assumption that all two-
phase equilibria can be represented by straight lines in a P-T diagram.24,26,35-38 
The dP/dT slopes of the P-T melting curves can be calculated using the enthalpy and 
volume changes at ordinary pressure (P = 0 MPa) from DSC data (Table 3) and specific 
volume measurements (equations 1 to 4a). This results in dP/dTI-liq = 4.80 MPa K-1 and 
dP/dTIII-liq = 3.89 MPa K-1 and leads to the following equations (P in MPa, T in K, the 
subscript T in the equation number indicates “topological”): 
 
PI-liq = -2037 + 4.80 T       (5T) 
 
and  
 
PIII-liq = -1604 + 3.89 T       (6T) 
 
for lines I-liq and III-liq, which intersect at TI-III-liq = 477 K and PI-III-liq = 252 MPa. This is 
higher than the coordinates obtained through the high-pressure data points (section 
4.3); however, it leads to the same topological picture of two converging equilibrium 
lines with increasing pressure. 
Because the III-I equilibrium curve also passes through triple point I-III-liq its equation 
(P and T in MPa and K respectively) 
 
PIII-I = -315 + 1.187 T       (7T), 
 
has been determined using the mean value ∆III→Ih = 27.5 J g-1 (Table 3) and ∆III→Iv = 
0.0486 cm3 g-1 at 477 K (eqs. 1 and 3). Eq. 7T leads to the transition point I-III at ordinary 
pressure of TI-III-vap = 266 K at P = 0 MPa. 
The experimental melting point of the II-liq equilibrium reported in the literature has 
not convincingly been determined. Nevertheless, if TII

liq = 413 K is used together with 
Page 20 of 55
John Wiley & Sons, Inc.
Journal of Pharmaceutical Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 21
∆II→liqh = 211.5 J g-1 (the algebraic sum ∆II→Ih + ∆I→liqh = 24.4 + 187.1) and the volume 
change on melting, 0.1184 cm3g-1 calculated with equations 2 and 4b (at 413 K), dP/dTII-
liq becomes 4.32 MPa K-1. This leads to the following relation for the melting curve of 
form II (P in MPa and T in K): 
 
PII-liq = - 1786 + 4.32 T       (11T) 
 
Although this value of dP/dTII-liq is different from that reported in section 4.4, the 
topological method leads to the same inequality in the slopes of the melting equilibria 
(III-liq < II-liq < I-liq). 
The coordinates of the “topological“ triple points I-II-liq, I-III-liq and II-III-liq calculated 
with equations 5T, 6T and 11T are compiled in Table 4 and compared with the values 
obtained or inferred from the high-pressure data. 
If the literature value of 415 K is used for TII-liq, equation 11T becomes  
 
PII-liq = -1769 + 4.26 T       (11T’) 
 
which leads in combination with equations 5T and 6T, to the same inequalities TI-II-liq > TI-
III-liq and PI-II-liq > PI-III-liq (Table 4). Clearly the melting point of form II must be located in 
between those of forms I and III and it can thus be concluded that topological tools to 
construct a phase diagram can be a powerful means to verify and complete a phase 
diagram partially obtained by experimental data. 
 
Table 4. Triple point coordinates I-II-liq, I-III-liq and II-III-liq determined directly 
from high-pressure data and by the Clapeyron equation (topological approach) 
 I-II-liq I-III-liq II-III-liq 
 P/MPa T/K P/MPa T/K P/MPa T/K 
High-pressure data 182 450 153 443 117 436 
Topological data with 
TII-liq = 413 K 
501 529 250 477 27 419 
Topological data with 
TII-liq = 415 K 
361 500 250 477 120 443 
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4.5.2 Triple points involving the vapor phase 
Lines 4, 5 and 6 cross respectively triple points I-II-vap, I-III-vap and II-III-vap where the 
vapor pressure is the saturating vapor pressure of the involved condensed phases at the 
respective triple points. Their pressure coordinates can be approximately determined 
with the experimental vapor pressure results for form II obtained by Picciochi et al.4 
These vapor pressures in the temperature range of 356.66 K to 374.44 K have been 
fitted with the Clausius-Clapeyron equation, leading to the following expression (P in 
pascal, T in kelvin): 
 
ln(PII-vap)= 36.7 - (14143/T)  r2 = 0.996    (12) 
 
From eq. 12, an average sublimation enthalpy is obtained ΔII →vapH = 14143 R (the gas 
constant R = 8.3145 J K-1mol-1), which equals 117.6 kJ mol-1 (827.2 J g-1). 
At the temperature of the triple point I-II-vap, 373 K, the vapor pressure of form I equals 
that of form II. Thus, with ΔI→vapH = ΔII→vapH - ΔII→IH = 117592 – 3462 = 114130 J mol-1, 
the vapor pressure of form I is given by (P/Pa, T/K): 
 
ln(PI-vap) = 35.6 - (13727/T)       (13) 
 
This leads to a vapor pressure of 26 Pa at the melting point of form I or triple point 
TI-liq-vap = 424.5 K. 
 
At the temperature of triple point II-III-vap, 316 K, the vapor pressure of form III equals 
that of form II. Thus, with ΔIII→vapH = ΔII→vapH + ΔII→IIIH = 117592 + 441 = 118033 J mol-1, 
the vapor pressure of form III is given by (P/Pa, T/K): 
 
ln(PIII-vap) = 36.9 - (14196/T)       (14) 
 
The vapor pressure of form I at the temperature (TI-liq = 424.46 K) of triple point I-liq-
vap is the same as the vapor pressure of the liquid phase. With Δliq→vapH = ΔI→vapH - 
ΔI→liqH = 114130 – 26598 = 87532 J mol-1, this leads to (P/Pa, T/K): 
 
ln(Pliq-vap) = 28.0 - (10528/T)       (15) 
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Eq. 15 gives a vapor pressure of 12 Pa at TIII-liq = 412.3 K. 
 
By setting eqs. (12) and (15) equal, the pressure and temperature of the melting triple 
point of form II can be found: P = 17.3 Pa and  T = 418 K , i.e. greater than TIII-liq and close 
to the values of 413 K (see above) and 415 K.3  (If TII-liq = 413 K is used, the vapor 
pressure is found to be 11.7 Pa with equation 12). 
 
The last vapor pressure to be determined is the vapor pressure at triple point I-III-vap, 
whose temperature was found to be 362 K from PTA experiments. By setting equal 
equations 13 and 14, the temperature of this triple point (at which the vapor pressure of 
the two forms should be equal) is found to be 360.8 K (i.e. the same value as 362 K, the 
difference is due to rounding). Using either of equations 13 and 14, the vapor pressure is 
found to be ≈ 0.1 Pa, slightly greater than the vapor pressure of form II of 0.093 Pa found 
with equation 12 (at 362 K), thus indicating that, at 362 K, the I-III-vap triple point is 
metastable with respect to the II-vap equilibrium. The results can be summarized 
topologically by representing the exponential curves as straight lines; the relative 
positions of the triple points involving the vapor phase are depicted in Figure 6. 
 
Figure 6. Topological representation of the two-phase equilibria involving the vapor 
phase in the P – T diagram of piracetam: 7 = liquid-vapor equilibrium, 8 = I-vapor, 9 = II-
vapor, 10 = III-vapor 
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5 Concluding remarks 
Piracetam polymorphism is a case that clearly demonstrates how delicate the 
determination of the stability hierarchy of polymorphs can be, in particular if only 
transition temperature inequalities are used. Moreover, when a melting temperature is 
not known, the case becomes even more difficult. 
It has been demonstrated how the stability hierarchy of forms I, II, and III was inferred 
from experimental results that do not rely on the measured solid-solid transition 
temperatures by DSC; the latter are heating-rate dependent and randomly distributed in 
relation to each other. High-pressure measurements (isothermal pressure dependent, 
and isobaric temperature dependent) provided the I-II-III triple point and the two 
equilibria II-I and III-I with which the position of the third solid-solid equilibrium III-II 
could be determined. 
The inequalities between the slopes of the solid-solid equilibrium curves involving 
forms I, II and III were experimentally obtained and obey the sequence dP/dTI-II > 
dP/dTI-III > dP/dTII-III. These inequalities can also be inferred from calorimetric and 
volumetric data obtained at “ordinary“ pressure, thus without explicit high-pressure 
measurements. Independent of the temperature coordinate, the inequality in the slopes 
can be calculated using the Clapeyron equation with the enthalpies of transition in J g-1 
from Table 3 (∆II→Ih = 24.4, ∆III→Ih = 27.5 and inferred ∆III→IIh = 3.1) and with the 
differences in the specific volumes in cm3 g-1 at for instance 100 K, 300 K and 500 K 
using equations 1, 2 and 3. In each case, one finds T(dP/dTI-II) > T (dP/dTI-III) > T 
(dP/dTII-III) (see calculations in Table S11 in the supporting information). These three 
slopes will intersect at a single temperature, the triple point I-II-III, which leads to the 
unambiguous conclusion that the inequality in the temperatures of triple points I-II-vap, 
I-III-vap and II-III-vap  (i.e. at P = 0 MPa) must be TI-II-vap > TI-III-vap > TII-III-vap, without 
resorting to the temperatures found by DSC for transitions II→I and III→I. 
 
To conclude, the P-T diagram for the phase relationships involving the three solid forms 
(I, II, and III) of piracetam can be topologically drawn as presented in figure 7a, in which 
all two-phase equilibria are present, or in figure 7b in which only stable equilibria and 
subsequent stable phase regions are present. On increasing the pressure, forms I and II 
both transform to form III, which is the stable phase at low temperature, including room 
temperature (<316 K), and high pressure. Thus, the conclusion from previous studies 
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that form III is the stable form at room temperature3-5 has been correct, but for the 
wrong reasons. Moreover, a stable domain for form II was in most cases overlooked 
(Figure 7b). 
 
 
Figure 7a. Complete topological P - T diagram for the phase relationships involving 
forms I, II and III of piracetam. Two-phase equilibrium curves: same numbering as in 
Figures 5 and 6. Stability ranking: same as in figure 6. 
 
 
Figure 7b. Topological representation of the stable P-T diagram. The stable phase 
regions are shown and delimited by the equilibrium curves connecting the five stable 
triple points (from ten in total). Form III is stable under ambient conditions. 
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Figure Captions 
 
Figure 1. Sublimation-condensation of piracetam crystals in a silica tube subjected to a 
temperature gradient for 6 days. The initial sample (form III) was placed in the small 
container on the left-hand side and maintained at 414 K. 
 
Figure 2. Onset temperatures of transitions II→I (solid squares), III→I (open circles) 
and melting of form I (solid diamonds) (A) of samples obtained by different methods 
and heated at 5 or 10 K min-1 (see for details Table S2 to S5) and (B) as a function of the 
heating rate. 
 
Figure 3. Specific volumes of piracetam forms I (open circles, eq. 1), II (solid diamonds, 
eq. 2) and III (solid circles, eq. 3) as a function of temperature from high-resolution X-
ray powder diffraction and comparison with volumes from single crystal structures (a: 
ref 8, b and c: ref 11). The experimental (eq. 4a, open diamonds) and calculated (eq. 4b, 
dashed line, see text) specific volumes of liquid piracetam are also provided. 
 
Figure 4. Pressure-temperature phase diagram of the phase transitions of piracetam 
with experimental data points only. Fusion of form I: squares, fusion of form III: 
diamonds, III→I: plus sign, II→IPTA: circles, and II→IHP-DTA: triangles. 
 
Figure 5a. Location of the triple points in the P-T region involving only condensed 
phases. Two-phase equilibrium curves: 1: I-liq, 2: II-liq, 3: III-liq, 4: I-II, 5: I-III, and 6: II-
III. Filled circles: stable triple points, half-filled circles: metastable triple points. Solid 
lines: stable equilibria, dashed lines: metastable equilibria, dotted lines: super –
metastable equilibria. Stable phase regions: dark grey: liquid, white: form I, medium 
grey: form II, light grey: form III. 
Figure 5b. Detail of the P-T diagram with the three triple points along the liq-vap curve 
(= x-axis): solid circle: I-liq-vap, stable, half-filled circle: II-liq-vap, metastable, open 
circle: III-liq-vap, super-metastable. The diagram shows the same two-phase 
equilibrium lines as in Figure 5a. Stable phase regions: see Figure 5a. 
 
Figure 6. Topological representation of the two-phase equilibria involving the vapor 
phase in the P – T diagram of piracetam: 7 = liquid-vapor equilibrium, 8 = I-vapor, 9 = II-
vapor, 10 = III-vapor 
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Figure 7a. Complete topological P - T diagram for the phase relationships involving 
forms I, II and III of piracetam. Two-phase equilibrium curves: same numbering as in 
Figures 5 and 6. Stability ranking: same as in figure 6. 
Figure 7b. Topological representation of the stable P-T diagram. The stable phase 
regions are shown and delimited by the equilibrium curves connecting the five stable 
triple points (from ten in total). Form III is stable under ambient conditions. 
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Figure 1. Sublimation-condensation of piracetam crystals in a silica tube subjected to a temperature gradient 
for 6 days. The initial sample (form III) was placed in the small container on the left-hand side and 
maintained at 414 K.  
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Figure 2. Onset temperatures of transitions II→I (solid squares), III→I (open circles) and melting of form I 
(solid diamonds) (A) of samples obtained by different methods and heated at 5 or 10 K min-1 (see for 
details Table S2 to S5) and (B) as a function of the heating rate.  
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Figure 3. Specific volumes of piracetam forms I (open circles, eq. 1), II (solid diamonds, eq. 2) and III (solid 
circles, eq. 3) as a function of temperature from high-resolution X-ray powder diffraction and comparison 
with volumes from single crystal structures (a: ref 8, b and c: ref 11). The experimental (eq. 4a, open 
diamonds) and calculated (eq. 4b, dashed line, see text) specific volumes of liquid piracetam are also 
provided.  
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Figure 4. Pressure-temperature phase diagram of the phase transitions of piracetam with experimental data 
points only. Fusion of form I: squares, fusion of form III: diamonds, III→I: plus sign, II→IPTA: circles, and 
II→IHP-DTA: triangles.  
79x79mm (600 x 600 DPI)  
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Figure 5a. Location of the triple points in the P-T region involving only condensed phases. Two-phase 
equilibrium curves: 1: I-liq, 2: II-liq, 3: III-liq, 4: I-II, 5: I-III, and 6: II-III. Filled circles: stable triple 
points, half-filled circles: metastable triple points. Solid lines: stable equilibria, dashed lines: metastable 
equilibria, dotted lines: super –metastable equilibria. Stable phase regions: dark grey: liquid, white: form I, 
medium grey: form II, light grey: form III.  
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Page 35 of 55
John Wiley & Sons, Inc.
Journal of Pharmaceutical Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  
 
 
Figure 5b. Detail of the P-T diagram with the three triple points along the liq-vap curve (= x-axis): solid 
circle: I-liq-vap, stable, half-filled circle: II-liq-vap, metastable, open circle: III-liq-vap, super-metastable. 
The diagram shows the same two-phase equilibrium lines as in Figure 5a. Stable phase regions: see Figure 
5a.  
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Figure 6. Topological representation of the two-phase equilibria involving the vapor phase in the P – T 
diagram of piracetam: 7 = liquid-vapor equilibrium, 8 = I-vapor, 9 = II-vapor, 10 = III-vapor  
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Figure 7a. Complete topological P - T diagram for the phase relationships involving forms I, II and III of 
piracetam. Two-phase equilibrium curves: same numbering as in Figures 5 and 6. Stability ranking: same as 
in figure 6.  
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Figure 7b. Topological representation of the stable P-T diagram. The stable phase regions are shown and 
delimited by the equilibrium curves connecting the five stable triple points (from ten in total). Form III is 
stable under ambient conditions.  
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Table 1. Specific volumes (v) from the literature of the three solid forms of 
piracetam obtained under ambient conditions 
Form System, space group v 
/cm3 g-1 
T 
/K 
Ref. 
I Monoclinic P21/n 0.7661 
0.7518 
R.T. 
150 
9 
7 
II Triclinic P-1 0.7383 
0.7094 
R.T. 
100 
10 
11 
III Monoclinic P21/n 0.7216 
0.7321 
0.7245 
0.7251 
0.7058 
R.T. 
R.T. 
R.T. 
290 
100 
12 
10 
13 
14 
11 
 
Table 2. Calorimetric data for piracetam forms I, II, and III from the 
literature 
TII-I 
/K 
∆II→Ih 
/J g-1 
TIII-I 
/K 
∆III→Ih 
/J g-1 
TI-liq 
/K 
∆I→liqh 
/J g-1 
TIII-liq 
/K 
∆III→liqh 
/J g-1 
Ref. 
382 
382 
23.71 
23.92 
393 
392 
26.45 
26.73 
- 
423 
- 
179.38 
- 
- 
- 
- 
14 
5 
348 or 377 21 390 26.7 426 180.7 413 206 3 
399 24 392 28 426 180 412 210 6 
382.7 22.72 394.4 26.24 425.9 176.6 or 
182.9 
  4 
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Table 3. Summary of the calorimetric data obtained for forms I, II, and III of 
piracetam from 5 series of DSC experiments (see Tables S2 to S5 in the 
Supporting Information) 
 Number 
of values 
Lowest 
value 
Highest 
value 
Mean Standard 
deviation 
TII-I /Ka 12 372.9 402.8 390.6 9.4 
TIII-I /Ka 18 363.3 406.9 389.0 12.5 
∆II→Ih/J g-1 23 22.9 25.9 24.4 0.9 
∆III→Ih/J g-1 26 25.2 30.1 27.5 1.2 
∆I→liqh/J g-1 49 174.9 195.4 187.1 4.3 
TI-liq/K 49 423.3 425.6 424.5 0.5 
∆III→liqh/J g-1 7 (205.0) 
207.1b 
(217.1) 
219.3b 
(211.5) 
213.6a 
4.4 
TIII-liq/K 7 411.9 412.8 412.3 0.34 
aAverage for 5 and 10 K min-1 only 
bValues adjusted for the presence of 1 mass% of methanol in form III, the 
measured apparent melting enthalpies are provided in parentheses. 
 
Table 4. Triple point coordinates I-II-liq, I-III-liq and II-III-liq determined 
directly from high-pressure data and by the Clapeyron equation 
(topological approach) 
 I-II-liq I-III-liq II-III-liq 
 P/MPa T/K P/MPa T/K P/MPa T/K 
High-pressure data 182 450 153 443 117 436 
Topological data with 
TII-liq = 413 K 
501 529 250 477 27 419 
Topological data with 
TII-liq = 415 K 
361 500 250 477 120 443 
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Table S1. Crystallographic data for piracetam polymorphs 
 Form I Form I Form II Form III Form III Form III Form III Form II Form III 
          
Space 
group 
P21/n P21/n P-1 P21/n P21/n P21/n P21/n P-1 P21/n 
a /Å 6.747 6.7254 6.403 16.376 6.525 16.403 6.503 6.3530 6.4539 
b /Å 13.418 13.2572 6.618 6.413 6.440 6.417 6.418 6.5278 6.3857 
c /Å 8.090 8.0529 8.556 6.493 16.463 6.504 16.416 8.3716 16.1814 
α /°   79.85     80.297  
β /° 99.01 98.603 102.39 92.21 92.19 92.05 92.087 78.226 92.05 
γ /°   91.09     89.048  
Vcell /Å3 723.36 709.92 348.58 681.38 691.29 684.160 684.69 334.96 666.45 
Z 4 4 2 4 4 4 4 2 4 
T/K R.T. 150 R.T. R.T. R.T. R.T. 290 100 100 
v/cm3g-1 0.766052 0.751816 0.738310 0.721597 0.732085 0.724538 0.725097 0.709449 0.705785 
Melting 
point 
   154°C  138°C    
Ref. 
(paper) 
9 7 10 12 10 13 14 11 11 
 
Table S2. First series of DSC experiments, performed in 1993 with a TA Instruments DSC10 Thermal Analyzer 
Origin/ 
comment 
Heating 
rate/ 
K min-1 
Mass/
mg 
Ttrans/K 
(onset) 
∆transH / 
J g-1 
Tfus/ 
K 
(onset) 
∆fusH/ 
J g-1 
Identification 
of the initial 
form 
As received. no 
recrystallization 
10 23.95 394.41 25.49 424.22 185.0 Form III 
As received. no 
recrystallization 
10 23.95 393.33 25.50 424.22 176.9 Form III 
Recrystallized 
from isobutanol 
10 14.60 394.32 23.71 423.94 182.6 Form II 
Recrystallized 
from isobutanol 
10 14.60 395.33 24.96 424.94 189.3 Form II 
Recrystallized 
from isobutanol 
10 14.60 395.31 23.97 424.94 181.1 Form II 
Recrystallized 
from isobutanol 
+5% water  
10 8.62 395.55 22.89 425.07 188.8 Form II 
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Table S3. Second series of DSC experiments, performed in 1996 with a TA Instruments DSC10 Thermal Analyzer 
Identification 
of the initial 
form 
Obtention 
footnotes 
Heating rate 
/K min-1 
Mass 
/mg 
Ttrans/K 
(onset) 
∆transH 
/J g-1 
Tfus/K 
(onset) 
∆fusH 
/J g-1 
Form III  a1 5 6.39 363.33 27.24 423.95 185.0 
Form II a2 5 9.13 377.84 24.21 425.18 183.5 
Form III  b 5 14.18 364.98 27.41 - - 
Form III c 5 7.21 368.74 28.24 423.69 190.5 
Form II d 5 5.58 372.35 23.04 425.24 186.2 
Form II e 5 18.07 378.97 24.67 424.39 186.2 
Form III f 5 13.93 383.14 27.07 424.65 184.5 
Form ? f2 5 10.33 - - 425.10 187.4 
Form III g 5 - 383.20 27.43 - - 
Form ? g2 5 19.59 - - 425.57 186.7 
Form III  h 10 11.00 396.60 28.00 425.37 192.5 
Form III i 10 11.67 406.86 26.78 425.26 189.1 
form III i 5 11.70 - - 412.65 205.0 
Form III  i 5 10.29 400.28 27.25 424.68 186.7 
Form III j1 5 18.37 397.58 27.23 424.72 186.0 
Form I j2 5 18.37 - - 424.34 184.5 
Form III k 5 12.66 390.12 27.74 424.71 188.3 
Form II l 5 - 399.00 23.56 - - 
Form II m 5 10.43 393.13 23.56 425.41 185.2 
Form II n 5 11.40 394.88 22.93 424.53 185.5 
a1 = after grinding form II with pestle and mortar. a2 = crystallized from isobutanol+5% water solution then ground with pestle and mortar. b = form III obtained after a 30-mn ball 
milling of form II (itself obtained by recrystallization from a solution in a mixture of isobutanol + 5% water). c = obtained after ball milling for 30 min of a form-II specimen containing  
1% of form III. d = obtained after ball milling of form I (itself obtained by heating form III to 403 K then quenching to room temperature). e = from form I recrystallized from the melt 
then annealed for 3.5 months at room temperature. f = form III submitted to a uniaxial pressure od 0.2 GPa.  f2 = unidentified form obtained by recrystallization from a solution in a 
mixture of isobutanol + 5% water then submitted to a uniaxial pressure of 0.2 GPa. g = after being subjected to a uniaxial pressure of 1 GPa. g2 = unidentified form obtained after 
heating to 407 K then subjected to a uniaxial pressure of 1 GPa. h = recrystallized from a solution in isobutanol. i = recrystallized from a solution in methanol then maintained under a 
dynamic vacuum for 1.5 month. j1 = specimen as received from the supplier. j2 = reheating of specimen j1 just after being cooled to room temperature. k = another specimen as 
received from the supplier. l and m = recrystallized from a solution in a mixture of isobutanol + 5% water. n = specimen as received from the supplier. 
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Table S4. Third series of experiments using a TA Instruments Q100 Thermal Analyzer, 2009, July 8, heating rate 10 K min-1, 
initial sample: form III 
Mass/mg T(III→I)/K 
(onset) 
∆III→IH/Jg-1 Tfus/K 
(onset) 
∆fusH/Jg-1 
 
- - - 423.33 187.8a 
4.39 - - 411.92 212.1b 
4.44 - - 412.16 214.6b 
6.44   412.75 214.9b 
5.48 391.94 28.4 424.46 190.7a 
4.10 - - 412.35 207.9b 
4.18 401.74 25.2 424.19 191.0a 
6.17 391.03 28.6 424.38 191.7a 
3.75 - - 412.63 217.1b 
3.15 397.65 28.2 424.26 192.7a 
amelting of form I 
bmelting of form III 
 
Table S5. Fourth series (4a, 4b, 4c) of experiments using a TA Instruments Q100 Thermal Analyzer July and August 2009 
Series 4a Heating 
rate 
K min-1 
Mass/
mg 
Ttrans /K 
(onset) 
∆transH/ 
J g-1 
 
Tfus/K 
(onset) 
∆fusH/ 
J g-1 
comments 
Form IIa 2 2.64 374.81 25.37 424.20 184.76  
Form IIIb 2 4.95 - - 411.95 208.89 Remains form III up 
to melting 
Form IIIc 
 
2 3.14 375.92 29.36 423.99 185.86 Initial form III that 
transforms to form I  
Form IIIc 10 3.05 384.44 28.61 424.43 179.96 Initial form III that 
transforms to form I 
aground with pestle and mortar 
bobtained after heating to 358 K 
cobtained after heating to 358 K then grinding with pestle and mortar 
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Table S5 cont. Fourth series 4ba 
Series 4ba Heating rate/  
K min-1 
Mass/ 
mg 
Ttrans/K 
(onset) 
∆transH/ 
J g-1 
Tfus/K 
(onset) 
∆fusH/ 
J g-1 
Form II 10 2.40 387.93 25.74 424.39 188.32 
Form IIb 20 2 .27 389.50 23.44 424.14 179.85 
Form IIb 15 1.92 390.53 23.28 424.36 174.90 
Form II 5 1.76 385.03 25.17 423.87 189.20 
Form II 7.5 2.20 387.95 25.93 424.75 195.14 
Form IIb 7.5 2.40 385.35 24.65 424.18 185.46 
Form IIb 12.5 1.87 388.44 24.43 424.31 184.14 
Form IIb 30 2.32 392.58 25.46 424.46 193.27 
Form II 18 2.05 385.65 25.41 424.32 189.75 
       
Form III 20 2.05 399.76 26.63 424.24 186.67 
Form III 15 1.93 399.10 26.19 424.85 185.46 
Form III 5 2.02 380.87 30.10 423.96 195.36 
Form III 7.5 3.00 382.45 28.31 423.80 187.11 
Form III 12.5 2.00 392.58 28.75 424.11 189.75 
Form III 30 2.53 394.94 27.58 424.21 192.61 
Form III 18 1.83 394.22 27.47 423.73 192.39 
aSeries 4b has been performed with the same aliquots of forms II and III ground with pestle and mortar. 
bAn additional very weak endothermic peak (∆H = 0.10-0.7 J g-1) is recorded at 410.15 – 411.53 K (onset). 
 
The mean values from series 4a and 4b: 
Form I: Mean Tfus,I = 424.23 K (std dev =0.29. std err.=0.07). Mean ∆fushI = 187.44 J/g (std dev.=5.38. std err.=1.24) 
Form III: Tfus,III = 411.95 K, ∆fushIII = 208.89 J/g 
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Table S5 cont. Fourth series 4c - Other measurements with ground forms II and III 
Form II  Heating rate/ 
K min-1 
Mass/ 
mg 
Ttrans/K 
(onset) 
25 2.68 397.59 
22 2.32 397.20 
50 2.80 395.80 
1 3.10 383.43 
Form III  25 3.14 385.71 
22 2.71 386.09 
1 2.75 387.84 
50 2.67 407.89 
      
Series 5. A fifth series of experiments has been performed with a Mettler-Toledo 822e thermal analyzer.  
A specimen of Form III (2.00 mg) showed a transition to form I (TIII→I =393.39 K (onset), ∆III→IH = 26.80 J g-1) on heating at a 10 K min-1 
rate followed by melting of form I at Tfus,I = 425.13K (onset), ∆fus,IH = 189.80 J g-1. 
A specimen of Form II (9.77 mg) heated at the same rate showed first a transition to form I at TII→I = 402.82 K (onset), ∆II→IH = 23.96 J g-1, 
then a small endothermic peak at 412.46 K (onset), ∆H = 0.40 J g-1, followed by melting of form I at Tfus,I = 425.07 K (onset), ∆fus,IH = 
189.31 J g-1. On cooling, crystallization started at 360.44 K, ∆crystH = −145 J g-1. On reheating at a 10 K min-1 rate, only the melting of form 
I was observed (Tfus,I = 423.52 K (onset), ∆fus,IH = 183.50 J g-1) thus indicating that the crystallization enthalpy previously observed 
should be ascribed to form I. 
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Table S6a. Unit-cell parameters (with standard deviations in parentheses) and specific volumes for piracetam forms I, II, and III 
as a function of temperature (measurement series 1). The X-ray powder diffraction data of form I were collected upon cooling, 
except for three of them (the parameters derived from these three datasets are marked with an asterisk). 
Form II triclinic 
T/K a/Å b/Å c/Å α/° β/° γ/° Vcell(II)/Å
3 v(II)/cm3 g-1 
298 6.395(2) 6.613(2) 8.531(4) 79.77(4) 102.38(3) 91.14(3) 346.7(2)    0.73432 
313 6.406(2) 6.621(3) 8.554(5) 79.79(4) 102.48(7) 91.21(4) 348.6(3) 0.73835 
333 6.400(3) 6.629(2) 8.568(5) 79.68(3) 102.56(8) 91.20(5) 349.0(3) 0.73919 
353 6.407(2) 6.637(2) 8.593(2) 79.64(2) 102.70(2) 91.18(3) 350.5(2) 0.74237 
373 6.401(2) 6.636(3) 8.612(3) 79.55(3) 102.79(3) 91.20(3) 350.7(3) 0.74280 
383 6.404(3) 6.654(3) 8.630(3) 79.56(2) 102.94(2) 91.09(2) 352.4(3) 0.74640 
 
 
Form I monoclinic (from Form II) 
T/K a/Å b/Å c/Å β/° Vcell (I)/Å
3 v(I)/ cm3 g-1 
298 6.759(2) 13.426(4) 8.102(2) 98.95(3) 726.2(4) 0.76906 
313 6.763(1) 13.454(2) 8.115(1) 99.06(1) 729.2(2) 0.77224 
323 6.769(1) 13.464(2) 8.120(1) 99.12(2) 730.6(2) 0.77372 
333 6.772(2) 13.477(3) 8.124(2) 99.10(3) 732.1(3) 0.77531 
353 6.776(2) 13.504(3) 8.136(2) 99.21(2) 734.8(3) 0.77817 
373 6.779(2) 13.526(2) 8.150(1) 99.31(2) 737.5(3) 0.78103 
383 6.780(1) 13.543(2) 8.158(1) 99.35(2) 739.1(2) 0.78272 
393 6.787(2)* 13.563(2)* 8.172(2)* 99.38(2)* 742.2(3)* 0.78600* 
398 6.793(2) 13.564(3) 8.170(2) 99.41(3) 742.6(3) 0.78643 
403 6.791(1)* 13.577(2)* 8.180(1)* 99.43(2)* 744.0(2)* 0.78791* 
413 6.797(2)* 13.588(2)* 8.190(2)* 99.48(2)* 746.1(3)* 0.79013* 
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Form III monoclinic 
T/K a/Å b/Å c/Å β/° Vcell (III)/Å
3 v(III)/ cm3 g-1 
298 6.513(3) 6.426(2) 16.419(3) 92.09(2) 686.7(3) 0.72723 
313 6.517(3) 6.435(3) 16.434(4) 92.13(2) 688.9(4) 0.72956 
333 6.529(2) 6.443(2) 16.475(2) 92.15(2) 692.6(3) 0.73348 
353 6.526(2) 6.449(2) 16.505(3) 92.17(2) 694.2(3) 0.73517 
373 6.533(2) 6.460(2) 16.518(5) 92.22(2) 696.6(3) 0.73771 
 
 
Form I monoclinic (from Form III) 
T/K a/Å b/Å c/Å β/° Vcell (I)/Å
3 v(I)/ cm3 g-1 
353 6.781(3) 13.502(3) 8.147(2) 99.12(4) 736.5(3) 0.77997 
383 6.784(2) 13.539(3) 8.166(2) 99.29(3) 740.2(3) 0.78389 
393 6.789(2) 13.562(2) 8.173(1) 99.39(2) 742.4(3) 0.78622 
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Table S6b. Lattice parameters and specific volumes of forms I, II and III as a 
function of temperature (measurement series 2) 
Form II 
T/K a/Å b/Å c/Å α/° β/° γ/° v/cm3g-1 
100 6.358 6.535 8.376 80.26 101.79 90.93 0.71104 
130 6.362 6.546 8.393 80.21 101.85 90.96 0.71387 
160 6.368 6.556 8.415 80.16 101.93 90.98 0.71719 
190 6.373 6.566 8.439 80.10 101.99 91.01 0.72061 
220 6.380 6.577 8.467 80.02 102.10 91.03 0.72452 
250 6.385 6.590 8.496 79.95 102.21 91.03 0.72855 
280 6.392 6.601 8.525 79.89 102.28 91.06 0.73273 
310 6.399 6.616 8.558 79.79 102.46 91.08 0.73729 
340 6.405 6.629 8.591 79.72 102.60 91.10 0.74172 
355 6.407 6.636 8.606 79.67 102.69 91.13 0.74365 
370 6.412 6.646 8.624 79.63 102.76 91.14 0.74660 
380 6.412 6.650 8.635 79.59 102.83 91.16 0.74770 
Form I from Form II 
400 6.789 13.556 8.174 90 99.35 90 0.78608 
410 6.792 13.567 8.181 90 99.37 90 0.78769 
420 6.796 13.580 8.188 90 99.40 90 0.78952 
Form III 
100 6.457 6.387 16.186 90 92.05 90 0.70647 
130 6.466 6.391 16.217 90 92.05 90 0.70925 
160 6.474 6.394 16.249 90 92.04 90 0.71187 
190 6.483 6.400 16.285 90 92.05 90 0.71510 
220 6.490 6.406 16.324 90 92.06 90 0.71826 
250 6.498 6.412 16.364 90 92.08 90 0.72157 
280 6.505 6.420 16.405 90 92.11 90 0.72505 
290 6.505 6.422 16.412 90 92.11 90 0.72558 
310 6.512 6.430 16.447 90 92.14 90 0.72881 
340 6.518 6.441 16.492 90 92.19 90 0.73270 
370 6.526 6.452 16.540 90 92.23 90 0.73697 
380 6.526 6.457 16.552 90 92.26 90 0.73806 
Form I from Form III 
390 6.789 13.556 8.136 90 99.63 90 0.78179 
400 6.789 13.562 8.158 90 99.61 90 0.78429 
410 6.791 13.571 8.172 90 99.62 90 0.78637 
420 6.792 13.583 8.176 90 99.664 90 0.78747 
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Table S7. Specific volume of molten piracetam as a function of temperaturea 
T/K Top of the 
melt 
/cm 
Bottom of 
the melt 
/cm 
Height of 
the melt 
/cm 
Volume of 
the melt 
/cm3 
Specific volume 
of the melt 
/cm3 g-1 
427.44 42.684 25.554 17.130 8.9408 0.88328 
427.44 42.684 25.530 17.154 8.9533 0.88451 
420.64 42.560 25.530 17.030 8.8886 0.87812 
420.64 42.550 25.496 17.054 8.9011 0.87936 
415.79 42.492 25.486 17.006 8.8761 0.87688 
410.93 42.432 25.500 16.932 8.8374 0.87307 
430.35 42.666 25.502 17.164 8.9585 0.88503 
430.35 42.678 25.500 17.178 8.9658 0.88575 
430.35 42.640 25.496 17.144 8.9481 0.88400 
435.21 42.710 25.486 17.224 8.9898 0.88812 
440.06 42.814 25.518 17.296 9.0274 0.89184 
444.92 42.848 25.486 17.362 9.0619 0.89524 
432.30 42.678 25.480 17.198 8.9763 0.88678 
422.58 42.539 25.480 17.059 8.9037 0.87962 
417.73 42.504 25.472 17.032 8.8896 0.87822 
415.79 42.482 25.472 17.010 8.8781 0.87709 
410.93 42.426 25.474 16.952 8.8479 0.87410 
408.02 42.378 25.474 16.904 8.8228 0.87162 
404.13 42.331 25.468 16.863 8.8014 0.86951 
401.22 42.293 25.468 16.825 8.7816 0.86755 
427.44 42.658 25.516 17.142 8.9470 0.88389 
418.70 42.538 25.512 17.026 8.8865 0.87791 
430.35 42.643 25.498 17.145 8.9486 0.88405 
440.06 42.787 25.498 17.289 9.0238 0.89147 
444.92 42.827 25.502 17.325 9.0426 0.89333 
449.78 42.884 25.502 17.382 9.0723 0.89627 
454.63 42.942 25.509 17.433 9.0989 0.89890 
454.63 42.987 25.512 17.475 9.1209 0.90107 
459.49 43.008 25.530 17.478 9.1224 0.90122 
469.20 43.180 25.536 17.644 9.2091 0.90978 
410.93 42.432 25.494 16.938 8.8406 0.87338 
408.99 42.390 25.500 16.890 8.8155 0.87090 
407.05 42.414 25.500 16.914 8.8280 0.87214 
405.10 42.404 25.500 16.904 8.8228 0.87162 
401.22 42.350 25.498 16.852 8.7957 0.86894 
396.36 42.302 25.516 16.786 8.7612 0.86554 
396.36 42.296 25.510 16.786 8.7612 0.86554 
aInner diameter of the cylindrical silica tube containing the melt measured at various 
heights from the bottom of the tube: 8.161, 8.157, 8.154, 8.149, 8 .140, 8.151 mm, Mean 
diameter: 8.152 mm (SD = 0.0073, SEM = 0.0030), Mass of piracetam: 10.1223 g 
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Table S8. Piezothermal analysis: experimental melting pressure of forms I and III 
as a function of temperature, the experimental enthalpy changes, and the specific 
volume changesa on melting 
Melting of form I 
T /K P /MPa ∆h /J g-1 ∆s /J g-1 K-1 ∆va /cm3 g-1 
424.46b 0 187.10b 0.44080b 0.072700 
428.1 20.0 186.41 0.43542 0.071816 
432.9 47.0 185.00 0.42769 0.070484 
435.4 64.2 187.82 0.43191 0.071145 
438.1 81.5 186.41 0.42487 0.070177 
Melting of form III 
412.34b 0 211.50b 0.51293b 0.11262 
412.60 1.4200 - - - 
417.90 31.700 - - - 
422.50 44.800 213.14 0.50506 0.11089 
425.60 59.300 208.22 0.48959 0.10749 
428.60 71.600 195.55 0.45653 0.10023 
432.50 92.100 211.03 0.48748 0.10703 
435.40 103.40 208.92 0.48044 0.10548 
438.40 121.80 209.62 0.47763 0.10487 
442.30 138.70 210.33 0.47552 0.10440 
a Volume changes have been calculated with the Clapeyron equation: ∆v = ∆s dP dT( )  
and dP/dT = 5.96 from equation 5a for the fusion of form I and 4.55 from equation 6a for 
the fusion of form III 
b Mean values at ordinary pressure 
 
The values for the entropy change of form III in Table S8 lead to the expressions (r2 = 
0.93): 
 
∆s/J g-1 K-1 = 1.09 – 0.00140*T/K = 0.513 – 0.000302*P/MPa   (S8a) 
 
The value ∆s = 0.45653 J g-1 K-1 has been ignored. 
 
The values for the specific volume change of form III in Table S8 lead to the expressions 
(r2 = 0.94):  
 
∆v/cm3 g-1 = 0.233 − 0.000292*T/K = 0.113 – 6.26*10-5*P/MPa  (S8b) 
 
The value Δv = 0.10023 cm3 g-1 has been ignored. 
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Table S9. Piezothermal analysis: experimental pressure for transitions III→I and 
II→I as a function of temperature, experimental enthalpy changes, and volume 
changesa on transition 
T/K P/MPa ∆h/J g-1 ∆s/J K-1 g-1 ∆va/cm3 g-1 
transition III→Ib 
378.00 33.800 30.248 0.080020 0.042431 
378.20 26.400 27.434 0.072538 0.038463 
381.90 42.000 31.654 0.082887 0.043951 
382.00 35.400 30.248 0.079182 0.041986 
382.90 47.400 30.951 0.080833 0.042862 
388.20 51.600 30.248 0.077918 0.041316 
393.00 61.700 31.654 0.080546 0.042710 
398.10 68.500 30.951 0.077747 0.041225 
402.80 82.300 32.358 0.080332 0.042596 
402.90 70.600 30.248 0.075075 0.039809 
407.90 83.300 31.654 0.077604 0.041150 
408.20 89.600 32.358 0.079270 0.042033 
410.30 89.300 31.654 0.077150 0.040909 
413.10 102.00 32.358 0.078329 0.041534 
413.10 103.00 33.765 0.081735 0.043340 
415.50 99.700 30.951 0.074491 0.039499 
418.00 105.20 33.061 0.079094 0.041940 
423.10 117.50 30.951 0.073153 0.038789 
432.90 136.80 33.765 0.077997 0.041358 
435.40 139.80 32.358 0.074318 0.039407 
Transition II→Ic 
T/K P/MPa ∆H/J g-1 ∆s/J K-1 g-1 ∆v/ cm3 g-1 
375.70 7.5000    
383.00 23.700 26.027 0.067956 0.028214 
387.90 34.800 23.917 0.061657 0.025599 
390.40 38.400 26.027 0.066668 0.027679 
393.90 47.200 26.027 0.066075 0.027433 
397.90 56.900 28.137 0.070715 0.029359 
400.30 65.500 28.841 0.072048 0.029913 
405.90 81.400 28.841 0.071054 0.029500 
a Calculated with the Clapeyron equation (see Table S8) and dP/dT = 1.89 MPa K-1 from 
eq. 7a for III→I and dP/dT = 2.41 MPa K-1 from eq. 8a for II→I 
b Mean ∆s = 0.078 J K-1 g-1 (σ = 0.003), mean ∆v = 0.0385 cm3 g-1 (σ = 0.0015) 
c Mean ∆s = 0.068 J K-1 g-1 (σ = 0.004), mean ∆v = 0.0282 cm3 g-1 (σ = 0.0015) 
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Table S10. Melting pressures and temperatures of form I and form III from HP-
DTA measurements obtained with 2 K min-1 
Melting of form I Melting of form III Transition III→I Transition II→I 
T/K P/MPa T/K P/MPa T/K P/MPa T/K P/MPa 
425.25 0 409.60 0 402.90 62.340 387.90 0 
433.15 55.390 415.08 22.462 408.30 75.470 392.00 10.190 
428.75 21.180 429.70 84.150 410.00 87.980 397.00 19.900 
429.45 31.080 435.00 112.92 415.10 101.97 396.70 30.060 
431.45 49.530 440.30 135.40 431.70 123.31 401.60 48.110 
432.35 63.420 449.60 176.27 438.70 144.68 402.90 62.340 
434.45 76.110 453.40 211.29   408.30 75.470 
435.75 89.010 448.75 184.31   410.00 87.980 
436.55 102.04 453.15 205.36   404.40 59.260 
426.95 16.640 453.55 214.90     
431.65 60.740       
 
Table S11. Inequalities in the dP/dT slopes of the equilibria I-II, I-III and II-III 
The temperature of triple point I-II-III does not need to be known, but the slopes of the 
two-phase equilibria can be calculated at a given temperature, for instance at 100 K, 300 
K or 500 K, assuming that the enthalpies and the specific volumes change little with 
pressure. 
 
Specific volumes as a function of temperature: 
v(I)/cm3g-1 = 0.7219 +(0.00016026 * T/K)   equation (1) 
v(II)/cm3g-1 = 0.69661 +(0.00013037 * T/K)   equation (2) 
v(III)/cm3g-1 = 0.69341 +(0.00011618 * T/K)  equation (3) 
 
 
T (K) 100 K 300 K 500 K 
vI 0.73793 0.76998 0.80203 
vII 0.70965 0.73572 0.76179 
vIII 0.70503 0.72826 0.75150 
vI-vIII 0.0329 0.04172 0.05053 
vI-vII 0.02828 0,03426 0.04024 
vII-vIII 0.00462 0.00646 0.01029 
 
With ∆III→Ih = 27.53 J/g and ∆II→Ih = 24.42 J/g,  ∆III→IIh = 3.11 J/g (from calculation) 
 
Slopes (MPa/K) 
 100 K 300 K 500 K 
dP/dT(I-III) 8.37 2.20 1.09 
dP/dT (I-II) 8.64 2.38 1.21 
dP/dT(II-III) 6.73 1.39 0.60 
 
Conclusion: dP/dTI-II > dP/dTI-III > dP/dTII-III 
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Figure S1. Examples of curves obtained with the piezo-thermal analyzer on decreasing 
the pressure (arrows along the abscissa). Curves A and B: thermal effects associated to 
transitions II→I and III→I at 388 K, respectively. Curve C: thermal effects recorded 
using a solvent-free specimen of form III. Curve D: thermal effect recorded using a 
specimen of form III within which about 1% of the crystallization solvent was kept, 
resulting in the melting of form III. 
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